Nobel prize-winning gene therapy partly restores sight in blind people

By Published On: October 8, 2026Last Updated: October 8, 2026
Nobel prize-winning gene therapy partly restores sight in blind people

Gene therapy partly restored sight in some blind people, with limited side effects reported in a 10-patient trial of an optogenetic treatment.

The approach, known as optogenetic therapy, uses light to switch nerve cells on and off, a technique recognised by the 2026 Nobel Prize in Physiology or Medicine.

It was previously shown to partly restore vision in one blind person in 2021.

Researchers have now reported results involving that patient and nine additional participants.

All 10 participants had advanced retinitis pigmentosa, a group of genetic disorders in which light-sensitive cells in the retina progressively lose function.

Ganglion cells, which transmit visual information from the retina to the brain, deteriorate less rapidly in retinitis pigmentosa than the light-sensitive cells primarily affected by the disease.

Dr José-Alain Sahel, a lead author of the study from the University of Pittsburgh Medical Center, said: “These cells are not the primary cells targeted by the disease, so that’s why they are good candidates for the therapy.”

The treatment involves a single injection into the eye containing a harmless synthetic virus. It delivers genetic instructions for producing a light-sensitive protein to a ring of surviving ganglion cells, making them sensitive to light.

Patients then use light-stimulating goggles that capture images of their surroundings and convert them into pulses of light at a single wavelength.

The pulses activate the modified ganglion cells, allowing the wearer to perceive a monochrome image.

The technique does not depend on the specific genetic cause of a patient’s sight loss.

Researchers treated only the eye with the poorest vision in each participant and followed outcomes for up to five years.

One severe eye-related side effect occurred and was resolved within minutes. No side effects related to the therapy were reported elsewhere in the body.

Six of the 10 participants had clinically meaningful improvements in light sensitivity after treatment.

Some also improved at visual tasks while wearing the goggles, including detecting, locating and touching a notebook, locating a door and walking along a line.

Participants who spent more time training with the goggles tended to perform better on these tasks.

Prof Botond Roska, director of the Institute of Molecular and Clinical Ophthalmology Basel and a lead author of the study, said: “What we can say for sure is that the concept of optogenetics is valid for vision restoration.”

However, the treatment did not restore detailed vision.

Roska said: “They can detect objects, but they cannot yet detect faces.”

Researchers linked this limitation to the ring-like arrangement of the treated ganglion cells around the fovea, the small part of the retina responsible for sharp central vision.

Roska said the next aim is to work towards restoring high-resolution vision, with the hope of achieving this within five to 10 years.

Mark Hankins, professor of visual neuroscience at the University of Oxford, who was not involved in the research, said the findings provided reassurance about the safety of the approach and its use in people who retain some residual vision.

He said: “They’re baby steps, but they’re critical.”

Teen receives UK's first testicular tissue transplant in fertility breakthrough
UK launches £80m dementia tech challenge